Brian J Carroll

US Patent:

8410178, Apr 2, 2013

Filed:

Oct 28, 2011

Appl. No.:

13/284852

Inventors:

Brian J. Carroll - Gig Harbor WA, US
Gary Darland - Gig Harbor WA, US
Anuradha Desai - Gig Harbor WA, US
Veera Konda - Gig Harbor WA, US
Clinton J. Dahlberg - Port Orchard WA, US
Jan Urban - Gig Harbor WA, US

Assignee:

KinDex Therapeutics, LLC - Seattle WA

International Classification:

A61K 31/12
C07C 49/00

US Classification:

514690, 568379

Abstract:

The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (−)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, activate GPR120, inhibit inflammation, and treat conditions responsive to PPARγ modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.

US Patent:

8410179, Apr 2, 2013

Filed:

Mar 14, 2012

Appl. No.:

13/420062

Inventors:

Brian J. Carroll - Gig Harbor WA, US
Gary Darland - Gig Harbor WA, US
Anuradha Desai - Gig Harbor WA, US
Veera Konda - Gig Harbor WA, US
Clinton J. Dahlberg - Port Orchard WA, US
Jan Urban - Gig Harbor WA, US

Assignee:

KinDex Therapeutics, LLC - Seattle WA

International Classification:

A61K 31/12
C07C 49/00

US Classification:

514690, 568379

Abstract:

The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (−)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, activate GPR120, inhibit inflammation, and treat conditions responsive to PPARγ modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.

US Patent:

20100137449, Jun 3, 2010

Filed:

Dec 10, 2008

Appl. No.:

12/331887

Inventors:

Matthew L. Tripp - Gig Harbor WA, US
John G. Babish - Brooktondale NY, US
Jeffrey S. Bland - Fox Island WA, US
Veera Konda - Gig Harbor WA, US
Anu Desai - Gig Harbor WA, US
Gary Darland - Gig Harbor WA, US
Brian J. Carroll - Gig Harbor WA, US
James S. Traub - Boulder CO, US
Linda M. Pacioretty - Brooktondale NY, US
Dennis Emma - Gig Harbor WA, US

Assignee:

METAPROTEOMICS, LLC - San Clemente CA

International Classification:

A61K 31/122
A61P 35/00
A61P 9/10

US Classification:

514685, 514689, 514690

Abstract:

Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.

US Patent:

20110257074, Oct 20, 2011

Filed:

Dec 10, 2009

Appl. No.:

12/634877

Inventors:

Brian J. Carroll - Gig Harbor WA, US
Clinton J. Dahlberg - Port Orchard WA, US
James S. Traub - Boulder CO, US

Assignee:

Metaproteomics, LLC - San Clemente CA

International Classification:

A61K 38/02
A61K 31/122
A61P 25/04
A61P 19/02
A61P 3/04
C07C 45/78
A61P 3/06

US Classification:

514 11, 568366, 514690

Abstract:

Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form.

US Patent:

20110275721, Nov 10, 2011

Filed:

Dec 10, 2009

Appl. No.:

13/132492

Inventors:

Brian J. Carroll - Gig Harbor WA, US
Clinton J. Dahlberg - Port Orchard WA, US
James S. Traube - Boulder CO, US

Assignee:

Metaproteomics, LLC - San Clemente CA

International Classification:

A61K 31/122
C07C 45/80

US Classification:

514690, 568366

Abstract:

Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form.

US Patent:

20130337092, Dec 19, 2013

Filed:

May 17, 2013

Appl. No.:

13/897080

Inventors:

Andrea Lyra HELLER - Gig Harbor WA, US
Anu DESAI - Gig Harbor WA, US
Brian CARROLL - Gig Harbor WA, US
Matthew L. TRIPP - Gig Harbor WA, US
Jeffrey S. BLAND - Fox Island WA, US

Assignee:

METAPROTEOMICS, LLC - Aliso Viejo CA

International Classification:

A61K 36/87
A61K 36/48
A61K 36/28
A61K 36/53
A61K 36/736
A61K 36/54
A61K 31/366
A61K 31/216
A61K 36/31
A61K 36/42
A61K 31/353
A61K 36/45
A61K 31/7048

US Classification:

424732

Abstract:

Phytonutrient based compositions and methods of using the same for preventing, reducing, or treating genetic damage induced by environmental toxins are disclosed. Additionally, said compositions and methods are used to reduce oxidized low density lipoproteins (OxLDL), myeloperoxidase (MPO), and plasminogen activator inhibitor-1 (PAI-1).

US Patent:

20180297934, Oct 18, 2018

Filed:

Nov 27, 2017

Appl. No.:

15/823448

Inventors:

- Seattle WA, US
Jan URBAN - Port Orchard WA, US
Anuradha DESAI - Bellevue WA, US
Clinton J. DAHLBERG - Port Orchard WA, US
Brian J. CARROLL - Gig Harbor WA, US

International Classification:

C07C 225/14
C07C 49/743
C07C 49/707
C07C 69/612
C07C 69/28
A61K 31/122
C07C 69/78
C07C 69/96
C07C 59/90
A61K 31/135
C07C 251/42

Abstract:

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.

US Patent:

20150119461, Apr 30, 2015

Filed:

Jan 9, 2015

Appl. No.:

14/593164

Inventors:

- Seattle WA, US
Jan URBAN - Port Orchard WA, US
Anuradha DESAI - Bellevue WA, US
Clinton J. DAHLBERG - Port Orchard WA, US
Brian J. CARROLL - Gig Harbor WA, US

International Classification:

C07C 225/14
C07C 69/02
C07C 59/90
C07C 69/78
C07C 69/614
C07C 69/22
C07C 69/96

US Classification:

514512, 560129, 514552, 514546, 558260, 560106, 514544, 560105, 514532, 564455, 514659, 564384, 514655, 562503, 514557

Abstract:

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.